MRRBIZ: NSCLC Therapeutics In Asia-Pacific Market To 2019: Worldwide Industry Share, Investment Trends, Growth, Size, Strategy And Forecast Research Report

Markets Research Reports.biz added deep and professional market research reports on "NSCLC Therapeutics In Asia-Pacific Markets To 2019 - Personalized Therapies Focus On Untapped Segment Of Squamous Cell Carcinoma To Expand Treatment Pool" Market Analysis and Overview. Visit: http://www.marketresearchreports.biz/analysis-details/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
MarketResearchReports.biz
NSCLC Therapeutics In Asia-Pacific Market To 2019

(PRWEB) March 28, 2014

Research Report On the leading business intelligence provider, has released its latest research: ‘NSCLC Therapeutics in APAC Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool’, which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by 2019.

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool.

The key drivers for this growth include an aging population, an increasing number of NSCLC incident cases and the expected launch of promising therapies. The launch of premium-priced novel antibodies and immunotherapies in the first and second lines of therapy, including Boehringer Ingelheim’s Gilotrif, Eli Lilly’s necitumumab, Bristol-Myers Squibb’s Yervoy (ipilimumab) and nivolumab, Pfizer’s dacomitinib and Novartis’s LDK378 are set to drive the market during the forecast period. However, the recent implementation of a price ceiling on essential drugs,dominance of generic drugs in India and expected pricing restrictions in China could curtail the NSCLC market in APAC countries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in Australia, China, India and Japan. It includes:

A brief introduction to NSCLC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
In-depth analysis of currently marketed drugs for NSCLC, including analysis of their safety, efficacy, treatment patterns and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy
A comprehensive review of the pipeline for NSCLC, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period, analyzed on the basis of phase distribution, molecule type, program type, mechanisms of action and molecular target
Additional in-depth analysis of pipeline drug clinical trials, by Phase, trial size, trial duration and program failure rate, for each molecule type

To Download Full Report With TOC: http://www.marketresearchreports.biz/sample/sample/190520

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

Understand the NSCLC pipeline and the factors that indicate that it is becoming more innovative
Observe detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be
Follow the trends in NSCLC clinical trial size and duration in relation to industry averages
Assess the potential risk of future developmental programs for NSCLC therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates
Observe the potential growth patterns expected for the NSCLC market over the forecast period
Identify which countries are expected to contribute the most to this growth and devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the NSCLC market

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.4 Co-morbidities and Complications
2.5 Diagnosis
2.5.1 Physical Examination
2.5.2 Sputum Cytology
2.5.3 Imaging Tests
2.5.4 Biopsy
2.6 Classification
2.6.1 Adenocarcinoma

Read Complete Report With TOC: http://www.marketresearchreports.biz/analysis/190520

3 Marketed Products
3.1 Therapeutic Landscape
3.1.1 Alimta (pemetrexed disodium) – Eli Lilly and Company
3.1.2 Abraxane (nab-paclitaxel) – Celgene
3.1.3 Iressa (gefitinib) – AstraZeneca
3.1.4 Tarceva (erlotinib hydrochloride) – F. Hoffmann-La Roche
3.1.5 Xalkori (crizotinib) – Pfizer

4 Pipeline Products
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Patient Enrollment and Clinical Trial Size
4.4.3 Duration
4.5 Promising Drug Candidates in the Pipeline
4.5.1 Ramucirumab (IMC-1121B) – Eli Lilly and Company
4.5.2 Necitumumab (IMC-11F8) – Eli Lilly and Company

Latest Reports:

Global Medical Devices Survey 2013-2014 - Market Trends, Buyer Spend And Procurement Strategies In The Global Medical Devices Industry

http://www.marketresearchreports.biz/analysis-details/global-medical-devices-survey-2013-2014-market-trends-buyer-spend-and-procurement-strategies-in-the-global-medical-devices-industry

Global Medical Devices Survey 2013–2014: Market Trends, Buyer Spend and Procurement Strategies in the Global Medical Devices Industry” is a new report by ICD Research that analyzes how medical devices industry companies’ procurement expenditures, business strategies, and practices are set to change in 2013–2014. Additionally, this report presents a comparative analysis between two years of survey results (wherever applicable). This report gives you access to the category-level spending outlooks, budgets, supplier selection criteria, business challenges, and investment opportunities of leading purchase decision makers; it also identifies the future growth of buyers and suppliers, M&A, capital expenditure, staff hiring, and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities, as well as access to information categorized by region, company type, and size.

To Download FUll Report With TOC: http://www.marketresearchreports.biz/sample/sample/170276

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading global medical devices industry executives; it provides data and analysis on buyer expenditure, procurement, and developments within the global medical devices industry. It includes key topics such as global medical devices industry buyer expenditure and procurement behaviors and strategies, and identifies the threats and opportunities within the global medical devices industry, economic outlook trends, and business confidence within global medical devices industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, ICD Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value-chain of the global medical devices industry.

Global Oil And Gas Survey 2013-2014
http://www.marketresearchreports.biz/analysis-details/global-oil-and-gas-survey-2013-2014-market-trends-buyer-spend-and-procurement-strategies-in-the-global-oil-and-gas-industry

“Global Oil and Gas Survey 2013-2014: Market Trends, Buyer Spend and Procurement Strategies in the Global Oil and Gas Industry” is a new report by ICD Research that analyzes how oil and gas industry companies' procurement expenditures, business strategies, and practices are set to change in 2013-2014. Additionally, this report also presents a comparative analysis between two years of survey results (wherever applicable). This report gives you access to the category-level spending outlooks, budgets, supplier selection criteria, business challenges, and investment opportunities of leading purchase decision makers. The report also identifies the future growth of buyers and suppliers, MandA, capital expenditure, staff hiring, and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities, as well as access to information categorized by region, company type, and size.

To Download Full Report With TOC: http://www.marketresearchreports.biz/sample/sample/168926

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading global oil and gas industry executives; it provides data and analysis on buyer expenditure, procurement, and developments within the global oil and gas industry. The report includes key topics such as global oil and gas industry buyer expenditure and procurement behaviors and strategies, and identifies the threats and opportunities within the global oil and gas industry, economic outlook trends, and business confidence within global oil and gas industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives' attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, ICD Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value-chain of the global oil and gas industry.

About Us

Marketresearchreports.biz (http://www.marketresearchreports.biz) is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact US:

Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
E: sales(at)marketresearchreports(dot)biz